ABIVAX Société Anonyme (NASDAQ:ABVX) Stock Price Up 3%

ABIVAX Société Anonyme (NASDAQ:ABVX)’s share price rose 3% during mid-day trading on Tuesday . The company traded as high as $11.98 and last traded at $11.98. Approximately 29,368 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 82,510 shares. The stock had previously closed at $11.63.

Wall Street Analysts Forecast Growth

ABVX has been the topic of a number of recent analyst reports. Laidlaw initiated coverage on shares of ABIVAX Société Anonyme in a research note on Monday, July 29th. They issued a “buy” rating and a $48.00 target price on the stock. Guggenheim assumed coverage on shares of ABIVAX Société Anonyme in a research note on Monday, April 29th. They set a “buy” rating and a $50.00 price objective on the stock. Piper Sandler assumed coverage on shares of ABIVAX Société Anonyme in a research note on Monday, April 29th. They set an “overweight” rating and a $42.00 price objective on the stock. Finally, BTIG Research assumed coverage on shares of ABIVAX Société Anonyme in a research note on Monday, May 20th. They set a “buy” rating and a $43.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, ABIVAX Société Anonyme currently has a consensus rating of “Moderate Buy” and an average price target of $36.50.

ABIVAX Société Anonyme Stock Up 2.8 %

The firm’s fifty day moving average price is $12.33 and its 200-day moving average price is $13.51. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.23.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Capstone Investment Advisors LLC boosted its holdings in shares of ABIVAX Société Anonyme by 9.0% in the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock valued at $900,000 after acquiring an additional 5,199 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of ABIVAX Société Anonyme in the first quarter valued at approximately $81,000. Kennedy Capital Management LLC boosted its holdings in shares of ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after acquiring an additional 31,331 shares in the last quarter. Ghisallo Capital Management LLC bought a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $642,000. Finally, Janus Henderson Group PLC boosted its holdings in shares of ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after acquiring an additional 131,414 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.